Trials In Focus: Diverse Enrollment Lagging In Oncology, IQVIA Finds
Executive Summary
Also, CRO Syneos Health appointed an executive to its newly created DE&I position, while Alterity started a new Phase II study in multiple system atrophy, Antabio dosed the first patients in its Phase I study of an antibiotic for hospital infections, and Structure Therapeutics started a Phase IIa trial of its GLP-1 agonist in obesity and diabetes, with plans for a Phase IIb trial in 2024.
You may also be interested in...
NIH Would ‘Revolutionize’ Cancer Trial Recruitment With New ‘Moonshot’ Money
Rick Pazdur's wish for the National Cancer Institute to help industry speed US trial enrollment and diversity could get a boost if Congress fulfills Biden’s new fiscal year Cancer Moonshot funding request.
Syndax Readies FDA Filing In Leukemia After Stopping Revumenib Trial Early For Efficacy
The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.
Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.